Search results
Showing 256 to 270 of 2577 results for methods
Ibrutinib for treating relapsed or refractory follicular lymphoma [ID1251]
In development Reference number: GID-TA10223 Expected publication date: TBC
Cimavax for treating wild-type EGFR-positive non-small-cell lung cancer [ID1259]
In development Reference number: GID-TA10225 Expected publication date: TBC
In development Reference number: GID-TA10227 Expected publication date: TBC
MTX110 for untreated diffuse intrinsic pontine glioma [ID2695]
In development Reference number: GID-TA10573 Expected publication date: TBC
Atezolizumab for adjuvant treatment of resected high-risk muscle-invasive urothelial cancer [ID2730]
In development Reference number: GID-TA10623 Expected publication date: TBC
This guideline covers how general dental practice teams can convey advice about oral hygiene and the use of fluoride. It also covers diet, smoking, smokeless tobacco and alcohol intake.
This interim process statement has been produced to guide the development of good practice guidance. It provides an overview of the key process principles and describes all stages of the development of good practice guidance
ID6611 Obesity, overweight - semaglutide (including review of TA875)
Awaiting development Reference number: GID-TA11851 Expected publication date: TBC
This document is one of a series describing the processes and methods that NICE uses to carry out technology appraisals. It focuses on the technology appraisal processes
Benralizumab for treating severe eosinophilic asthma (TA565)
Evidence-based recommendations on benralizumab (Fasenra) for treating severe eosinophilic asthma in adults.
Awaiting development Reference number: GID-HTG10153 Expected publication date: TBC
Valoctocogene roxaparvovec for treating severe haemophilia A [ID3806]
Awaiting development Reference number: GID-TA10682 Expected publication date: TBC
In development Reference number: GID-TA10311 Expected publication date: TBC
Osteoporosis: assessing the risk of fragility fracture (CG146)
This guideline covers assessing the risk of fragility fracture in people aged 18 and over with osteoporosis. It aims to provide guidance on the selection and use of risk assessment tools in the care of adults at risk of fragility fractures in all NHS settings.
Exploratory economic modelling of SARS-CoV-2 viral detection point of care tests and serology tests
In development Reference number: GID-DG10038 Expected publication date: TBC